Dr Nicholas Silvestri reflects on promising new and existing treatment options, reinforcing a personalized approach and ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a Phase III clinical trial evaluating the efficacy and safety of telitacicept.

leading researchers to believe that myasthenia gravis may be caused by varying underlying mechanisms for different people. Researchers at UC San Diego's School of Biological Sciences used a ...

“Inebilizumab, based on its mechanism of action ... phase 3 study of inebilizumab in patients with generalized myasthenia gravis (MINT): topline data. Presented at: 2025 MDA Clinical ...

500 attendees in Phoenix, Arizona to educate and inform the MG community. Myasthenia gravis is a rare neuromuscular, autoimmune disease that impacts more than 90,000 individuals in the United ...

Researchers used a cutting-edge imaging technique to uncover new details about the mechanisms underlying the disease. People who suffer from the autoimmune disease myasthenia gravis experience ...